

Curriculum Vitae

Personal information **Ettore Domenico Capoluongo**

Work experience

Year	Degree/post graduation titles	Academy/Site
1994	MSc	Faculty of Naples Federico II
1995	Master of 2 nd Level in Biotechnology	University of Naples
1998	Specialization degree in <i>Clinical Pathology</i>	La Sapienza" School of Medicine, Rome, Italy
2001	Master of 2 nd Level in Accreditation of Clinical Laboratories	University of Camerino, Italy
2003	Researcher in Clinical Biochemistry and Clinical Molecular Biology	Faculty of Medicine Catholic University of Rome
2010	Specialization degree in <i>Medical Genetics</i>	Tor Vergata" School of Medicine, Rome, Italy
2014	Habilitated as <i>Full Professor</i> of Clinical Biochemistry and Clinical Molecular Biology	MIUR
2014	Habilitated as <i>Associate Professor</i> of Clinical Pathology	MIUR
dal 09/04/2018 al 09/04/2027)	Habilitated as <i>Full Professor</i> of General and Clinical Pathology	MIUR
2013-present	European Young Assessor – Italian and European Medical Agencies	AIFA/EMA
2015-2019	Scientific Advisor of Molipharma srl, a spin-off of Catholic	Catholic University of Rome
2017-2023	Elected Member of the Committee on Clinical Molecular Biology Curriculum (CMBC)	International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
2019	Full Professor of Clinical Biochemistry and Clinical	Faculty of Medicine

	Molecular Biology	University Federico II - Naples
2019-present	Head of Departmental Program on NGS application to Ovarian, Breast Prostate and Pancreatic cancers, pNET – Member of Multidisciplinary Oncological Group testing	Dept. Laboratory and Transfusion Medicine Federico II Hospital, Naples
2019-present	Consultant at EU-Commission DIGIT- CIRCABC European Commission as representative of European Federation of Laboratory Medicine (EFLM)	European Commission

2020-present	Co-Chair of Molecular LAB for COVID-2 testing (CORONET network Campania region)	CEINGE-FEDERICO II
2020-present	Member of Expert Alliance on Personalized Medicine	European Parliament
2020-2026	Member of the European Commission expert panels on medical devices (Expamed) and <i>in vitro</i> diagnostic medical devices	European Commission
2021-2023	Elected Member of the Board of Directors	Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO-Group)
2021-2023	Coordinator of the Operational Group on "Use of genomic technologies in the field of personalization of care"	Italian Society of Clinical Biochemistry and Molecular Biology (SIBioC)
2021	2nd level Master Degree in : Direction and Management of Laboratory Medicine Services	University eCampus, Italy
2021-present	Componente of the Task Force: European Regulatory Affairs (TF-ERA)	European Federation of Clinical Chemistry and

		Laboratory Medicine (EFLM)
2022-2024	Elected member of “Committee on Molecular Diagnostics (C-MD)”.	International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS		
Year	Role	Academy/Site
1996-1999	Fellow and researcher, Laboratory of Clinical Pathology,	San Gallicano Dermatologic Research Hospital, Rome, Italy
2009	Visiting Professor Department of Cancer Biology	Kimmel Cancer Hospital, Thomas Jefferson University, Philadelphia
2010	Visiting Scientist Department of Cancer Biology	Kimmel Cancer Hospital Thomas Jefferson University, Philadelphia
2013	Visiting Scientist at Neurobiology, Neurodegeneration & Repair Laboratory	NIH - National Eye Institute – Bethesda
<u>2014</u>	Visiting Scientist Neurobiology, Neurodegeneration & Repair Laboratory	NIH - National Eye Institute – Bethesda
<u>2017</u>	Visiting Professor at King Faisal Research Hospital —	Riyadh (Saudi Arabia)

Prof. Ettore Domenico CAPOLUONGO Specialized in Medical Genetics and Clinical Pathology Full Professor of Clinical Biochemistry and Clinical Molecular Biology - Department of Excellence in Molecular Medicine and Medical Biotechnology, Federico II University, Naples Director of Dept. of Clinical Pathology and Genomics – Ospedale per l’Emergenza Cannizzaro – Catania Member of the European Commission Expert Panel (‘Expanded’) on medical devices and invitro diagnostic. Member of the Committee on Molecular Diagnostics (C-MD) – IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) Coordinator of the Operational Group on “Use of genomic technologies in the field of treatment personalization” - Italian Society of Clinical Biochemistry and Clinical Molecular Biology - SIBioCLaboratory Medicine Elected member of the Board of Directors of the “Multicenter Italian Trials in Ovarian cancer and gynecological malignancies (MITO-Group)” Member of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Task Force: European Regulatory Affairs (TF-ERA)

Number of peer reviewed papers: 281

□ Number Chapters/monographs within books or encyclopedias: 9 □ H-Index (source Scopus) = 43

□ Google Scholar: H Index = 50; i10-index = 165

□ Recognized within the list of Top Italian Scientists (asreported inPlosBiol 2020)

□ Impact factor (IF): > 800 □ N. of Citations: 9951 (source: Google Scholar, updated at 30.5.2023)

2019: AWARD: Recognition for the outstanding contribution to the development of Clinical Molecular Biology as discipline of Laboratory Medicine. Award given by the Italian Society of Clinical Biochemistry and Clinical Molecular Biology – Laboratory Medicine (SIBioC)

Education and training

Second Degree Clinical Pathology

Università La Sapienza [01/11/1994 – 01 11/1998]

Address: Roma (Italy)

www.unina.it

Second Degree in Medical Genetics

Università Tor Vergata [01/11/2006 – 01/11/2010]

Address: Rome

www.uniroma2.it

LANGUAGE SKILLS

Mother tongue(s):

Italian

Other language(s):

English

LISTENING C1 READING C1 WRITING C2

SPOKEN PRODUCTION C1 SPOKEN INTERACTION C1

DIGITAL SKILLS

Microsoft word, Excel / Microsoft Office Word Excel Access Power Point Outlook

Additional information

Publications

<https://pubmed.ncbi.nlm.nih.gov/?term=capoluongo+e&sort=date>

1: Linder MW, Huggett JF, Baluchova K, Capoluongo ED, Payne DA, Salinas AV, Haselmann V, Ashavaid T, Pan S, Ahmad-Nejad P; IFCC Committee for Molecular Diagnostics C-MD. Results from an IFCC global survey on laboratory practices for the analysis of circulating tumor DNA. Clin Chim Acta. 2023 May 20;547:117398. doi: 10.1016/j.cca.2023.117398. Epub ahead of print. PMID: 37217114.

2: Horgan D, Capoluongo E, Dube F, Trapani D, Malapelle U, Rovite V, Omar MI, Alix-Panabières C, Rutkowski P, Bayle A, Hackshaw A, Hofman P, Subbiah V. Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicine. Diagnosis (Berl). 2023 Apr 10. doi: 10.1515/dx-2023-0022. Epub ahead of print. PMID: 37036891.

3: Lapini A, Caffo O, Conti GN, Pappagallo G, Del Re M, D'Angelillo RM, Capoluongo ED, Castiglione F, Brunelli M, Iacovelli R, De Giorgi U, Bracarda S. Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project. Crit Rev Oncol Hematol. 2023 Apr;184:103959. doi: 10.1016/j.critrevonc.2023.103959. Epub 2023 Mar 13. PMID: 36921782.

4: Vanstapel FJLA, Orth M, Streichert T, Capoluongo ED, Oosterhuis WP, Çubukçu HC, Bernabeu-Andreu FA, Thelen M, Jacobs LHJ, Linko S, Bhattoa HP, Bossuyt PMM, Meško Brguljan P, Boursier G, Cobbaert CM, Neumaier M. ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European <i>In-Vitro</i>-Diagnostics Regulation. Clin Chem Lab Med. 2023 Jan 31;61(4):608-626. doi: 10.1515/cclm-2023-0045. PMID: 36716120.

5: Nardelli C, Scaglione GL, Testa D, Setaro M, Russo F, Di Domenico C, Atripaldi L, Zollo M, Corrado F, Salvatore P, Pinchera B, Gentile I, Capoluongo E. Nasal Microbiome in COVID-19: A Potential Role of Corynebacterium in Anosmia. Curr Microbiol. 2022 Dec 30;80(1):53. doi: 10.1007/s00284-022-03106-x. PMID: 36583787; PMCID: PMC9802018.

6: Nunziato M, Scaglione GL, Di Maggio F, Nardelli C, Capoluongo E, Salvatore F. The performance of multi-gene panels for breast/ovarian cancer predisposition. Clin Chim Acta. 2023 Jan 15;539:151-161. doi: 10.1016/j.cca.2022.12.007. Epub 2022 Dec 13. PMID: 36521553.

7: Horgan D, Plebani M, Orth M, Macintyre E, Jackson S, Lal JA, Dube F, Kozaric M, Tumiene B, Salgado R, Schalken JA, Capoluongo ED, Carnielli M. The gaps between the new EU legislation on <i>in vitro</i> diagnostics and the on-the-ground reality. Clin Chem Lab Med. 2022 Nov 22;61(2):224-233. doi: 10.1515/cclm-2022-1051. PMID: 36409605.

8: Di Risi T, Cuomo M, Vinciguerra R, Ferraro S, Della Monica R, Costabile D, Buonaiuto M, Trio F, Capoluongo E, Visconti R, Riccio E, Pisani A, Chiariotti L. Methylome Profiling in Fabry Disease in Clinical Practice: A Proof of Concept. Int J Mol Sci. 2022 Oct 11;23(20):12110. doi: 10.3390/ijms232012110. PMID: 36292965; PMCID: PMC9602470.

9: Pavese F, Capoluongo ED, Muratore M, Minucci A, Santonocito C, Fuso P, Concolino P, Di Stasio E, Carbognin L, Tiberi G, Garganese G, Corrado G, Di Leone A, Generali D, Fragomeni SM, D'Angelo T, Franceschini G, Masetti R, Fabi A, Mulè A, Santoro A, Belli P, Tortora G, Scambia G, Paris I. BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making. Cancers (Basel). 2022 Sep 21;14(19):4571. doi: 10.3390/cancers14194571. PMID: 36230495; PMCID: PMC9559391.

10: Capoluongo ED, Pellegrino B, Arenare L, Califano D, Scambia G, Beltrame L, Serra V, Scaglione GL, Spina A, Cecere SC, De Cecio R, Normanno N, Colombo N,

Lorusso D, Russo D, Nardelli C, D'Incalci M, Llop-Guevara A, Pisano C, Baldassarre G, Mezzanzanica D, Artioli G, Setaro M, Tasca G, Roma C, Campanini N, Cinieri S, Sergi A, Musolino A, Perrone F, Chiodini P, Marchini S, Pignata S. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial. ESMO Open. 2022 Oct;7(5):100585. doi: 10.1016/j.esmoop.2022.100585. Epub 2022 Sep 23. PMID: 36156447; PMCID: PMC9512829.

<https://pubmed.ncbi.nlm.nih.gov/?term=capoluongo+e&sort=date>

Projects

Memberships

Member of the Committee on Molecular Diagnostics (C-MD) – IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) Coordinator of the Operational Group on "Use of genomic technologies in the field of treatment personalization" - Italian Society of Clinical Biochemistry and Clinical Molecular Biology - SIBioCLaboratory Medicine Elected member of the Board of Directors of the "Multicenter Italian Trials in Ovarian cancer and gynecological malignancies (MITO-Group)" Member of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Task Force: European Regulatory Affairs (TF-ERA)

Other Relevant Information